A large body of data indicates that activation of NF-κB contributes to the pathophysiology of ischemic stroke and, therefore, inhibition of NF-κB has been suggested as a potential therapeutic strategy against post-stroke brain inflammation [32,33,34]. The gene discussed is NFKB1; the disease is stroke disorder.